quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·7d
PRRelease
GE HealthCare Technologies Inc. logo
RadNet Inc. logo

GE HealthCare expands mammography collaboration with RadNet's DeepHealth subsidiary to extend global access to DeepHealth's AI-powered breast cancer screening solutions

GEHC· GE HealthCare Technologies Inc.RDNT· RadNet Inc.
Health Care
Original source

Companies

  • GEHC
    GE HealthCare Technologies Inc.
    Health Care
  • RDNT
    RadNet Inc.
    Health Care

Recent analyst ratings

  • Jan 15GEHCUpdateUBS$77.00
  • Jan 9RDNTUpdateKeyBanc Capital Markets$92.00
  • Oct 13GEHCUpdateBarclays$86.00
  • Oct 7GEHCUpdateCitigroup$83.00
  • Jun 13RDNTUpdateB. Riley Securities$69.00
  • May 5GEHCUpdateUBS$73.00

Related

  • PR18h
    GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents
  • SEC3d
    SEC Form DEFA14A filed by RadNet Inc.
  • SEC3d
    SEC Form DEF 14A filed by RadNet Inc.
  • PR7d
    The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
  • PR14d
    GE HealthCare announces digital integration between bkActiv™ intraoperative ultrasound system and Medtronic Stealth AXiS™ surgical navigation system
  • PR17d
    GE HealthCare to announce first quarter 2026 results on April 29, 2026
  • PR23d
    GE HealthCare Recommends Shareholders Reject "Mini-Tender" Offer by Potemkin Limited
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by RadNet Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022